HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) All Versions of this Article: gut.2006.101634v1 gut.2006.101634v2 56/6/772    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Malfertheiner, P Search for Related Content PubMed PubMed Citation Articles by Malfertheiner, P Topic Collections Editor's choice Related Article

Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report

¹ Otto-von-Guericke University of Magdeburg, Magdeburg, Germany
² INSERM U853, Bordeaux, France
³ Adelaide and Meath Hospital, Trinity College, Dublin, Ireland
⁴ University of Bologna, Bologna, Italy
⁵ Aberdeen University, Aberdeen, UK
⁶ VA Medical Center Houston, Texas, USA
⁷ McMaster University, Hamilton, Ontario, Canada
⁸ Henry-Dunant Hospital, Athens, Greece
⁹ University of Wisconsin Medical School, Milwaukee, USA
¹⁰ Erasmus MC University Medical Center, Rotterdam, Netherlands

Correspondence to:
Correspondence to:
Professor P Malfertheiner
Otto-von-Guericke-Universität Magdeburg, Medizinische Fakultät, Zentrum für Innere Medizin, Klinik für Gastroenterologie, Hepatologie und Infektiologie, Leipziger Straße 44, D-39120 Magdeburg, Germany; peter.malfertheiner{at}medizin.uni-magdeburg.de

Background: Guidelines on the management of Helicobacter pylori, which cover indications for management and treatment strategies, were produced in 2000.

Aims: To update the guidelines at the European Helicobacter Study Group (EHSG) Third Maastricht Consensus Conference, with emphasis on the potential of H pylori eradication for the prevention of gastric cancer.

Results: Eradication of H pylori infection is recommended in (a) patients with gastroduodenal diseases such as peptic ulcer disease and low grade gastric, mucosa associated lymphoid tissue (MALT) lymphoma; (b) patients with atrophic gastritis; (c) first degree relatives of patients with gastric cancer; (d) patients with unexplained iron deficiency anaemia; and (e) patients with chronic idiopathic thrombocytopenic purpura. Recurrent abdominal pain in children is not an indication for a "test and treat" strategy if other causes are excluded. Eradication of H pylori infection (a) does not cause gastro-oesophageal reflux disease (GORD) or exacerbate GORD, and (b) may prevent peptic ulcer in patients who are naïve users of non-steroidal anti-inflammatory drugs (NSAIDs). H pylori eradication is less effective than proton pump inhibitor (PPI) treatment in preventing ulcer recurrence in long term NSAID users. In primary care a test and treat strategy using a non-invasive test is recommended in adult patients with persistent dyspepsia under the age of 45. The urea breath test, stool antigen tests, and serological kits with a high accuracy are non-invasive tests which should be used for the diagnosis of H pylori infection. Triple therapy using a PPI with clarithromycin and amoxicillin or metronidazole given twice daily remains the recommended first choice treatment. Bismuth-containing quadruple therapy, if available, is also a first choice treatment option. Rescue treatment should be based on antimicrobial susceptibility.

Conclusion: The global burden of gastric cancer is considerable but varies geographically. Eradication of H pylori infection has the potential to reduce the risk of gastric cancer development.

Abbreviations: BabA2, blood group antigen binding adhesin 2; CagA, cytotoxin associated gene A; EHSG, European Helicobacter Study Group; GORD, gastro-oesophageal reflux disease; IDA, iron deficiency anaemia; ITP, idiopathic thrombocytopenic purpura; MALT, mucosa associated lymphoid tissue; NSAIDs, non-steroidal anti-inflammatory drugs; OipA, outer inflammatory protein A; PPIs, proton pump inhibitors; RCT, randomised controlled trial; SabA, sialic acid binding adhesion; UBT, ¹³C-urea breath test; VacA, vacuolating associated gene A

Keywords: H pylori; diseases; diagnosis; treatment; prevention

Related Article

Digest

Robin Spiller and Emad El-Omar
Gut 2007 56: 741. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

				C. Burucoa, M. Garnier, C. Silvain, and J.-L. Fauchere Quadruplex Real-Time PCR Assay Using Allele-Specific Scorpion Primers for Detection of Mutations Conferring Clarithromycin Resistance to Helicobacter pylori J. Clin. Microbiol., July 1, 2008; 46(7): 2320 - 2326. [Abstract] [Full Text] [PDF]

				N. S. Jafri, C. A. Hornung, and C. W. Howden Meta-analysis: Sequential Therapy Appears Superior to Standard Therapy for Helicobacter pylori Infection in Patients Naive to Treatment Ann Intern Med, June 17, 2008; 148(12): 923 - 931. [Abstract] [Full Text] [PDF]

				R. Krausse, G. Muller, and M. Doniec Evaluation of a Rapid New Stool Antigen Test for Diagnosis of Helicobacter pylori Infection in Adult Patients J. Clin. Microbiol., June 1, 2008; 46(6): 2062 - 2065. [Abstract] [Full Text] [PDF]

				U. Kiltz, J. Zochling, W. E. Schmidt, and J. Braun Use of NSAIDs and infection with Helicobacter pylori--what does the rheumatologist need to know? Rheumatology, May 13, 2008; (2008) ken123v1. [Abstract] [Full Text] [PDF]

				C.-W. Lee, B. Rickman, A. B. Rogers, Z. Ge, T. C. Wang, and J. G. Fox Helicobacter pylori Eradication Prevents Progression of Gastric Cancer in Hypergastrinemic INS-GAS Mice Cancer Res., May 1, 2008; 68(9): 3540 - 3548. [Abstract] [Full Text] [PDF]

				L. Fuccio, R. M. Zagari, and F. Bazzoli Could Increasing the Duration of Triple Therapy Be a Clinically Useful Strategy? Ann Intern Med, April 15, 2008; 148(8): 624 - 625. [Full Text] [PDF]

				B. C Delaney, M. Qume, P. Moayyedi, R. F A Logan, A. C Ford, C. Elliott, C. McNulty, S. Wilson, and F D R. Hobbs Helicobacter pylori test and treat versus proton pump inhibitor in initial management of dyspepsia in primary care: multicentre randomised controlled trial (MRC-CUBE trial) BMJ, March 22, 2008; 336(7645): 651 - 654. [Abstract] [Full Text] [PDF]

				L. Fuccio, M. E. Minardi, R. M. Zagari, D. Grilli, N. Magrini, and F. Bazzoli Meta-analysis: Duration of First-Line Proton-Pump Inhibitor Based Triple Therapy for Helicobacter pylori Eradication Ann Intern Med, October 16, 2007; 147(8): 553 - 562. [Abstract] [Full Text] [PDF]

				L Peyrin-Biroulet, J.-L. Gueant, A M C Rocha, G A Rocha, M C A Marino, and D M M Queiroz Does hyperhomocysteinaemia contribute to gastric carcinogenesis in Helicobacter pylori infected patients? * Author's reply Gut, October 1, 2007; 56(10): 1480 - 1481. [Full Text] [PDF]

				A. Zullo, V. De Francesco, C. Hassan, S. Morini, and D. Vaira The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysis Gut, October 1, 2007; 56(10): 1353 - 1357. [Abstract] [Full Text] [PDF]

				D. Vaira, A. Zullo, and N. Vakil Ethical Considerations of Comparing Sequential and Traditional Anti Helicobacter pylori Therapy Ann Intern Med, September 18, 2007; 147(6): 435 - 436. [Full Text] [PDF]

				D. Y Graham, Y. Yamaoka, R. M. Zagari, and F. Bazzoli One- or two-week triple therapy for Helicobacter pylori: questions of efficacy and inclusion of a dual therapy treatment arm * Authors' response Gut, July 1, 2007; 56(7): 1021 - 1023. [Full Text] [PDF]

				F. Megraud and P. Lehours Helicobacter pylori Detection and Antimicrobial Susceptibility Testing Clin. Microbiol. Rev., April 1, 2007; 20(2): 280 - 322. [Abstract] [Full Text] [PDF]